Key Takeaways
- • Janus Henderson launched the Horizon Discovering New Alpha (DNA) Fund on January 8, 2026, a globally diversified global equity strategy comprising approximately 50 high-conviction stocks designed to address investor concerns about performance concentration in a small group of mega-cap companies.
- • The DNA Fund is initially available exclusively to HSBC Private Bank and Premier clients across Asia, Europe, US Offshore, and the Middle East for a six-month period, representing a strategic distribution partnership between the two financial institutions.
- • The fund employs a proprietary optimization process and thematic investment approach focused on seven transformation areas: smarter automation, mobility, lifestyle shifts, longevity, biotechnology, sovereignty, and net zero 2.0, to identify companies with long-term growth potential across sectors and geographies.
- • Portfolio managers Richard Clode and Nick Harper lead the strategy, leveraging Janus Henderson's global team of specialists across technology, healthcare, financials, real estate, emerging markets, sustainability, and natural resources to deliver diversified exposure beyond traditional indices.
- • The DNA Fund addresses structural index concentration risks, particularly in large-cap and technology-heavy benchmarks (NASDAQ-100 at ~60% large-cap concentration, S&P 500 at ~80%), positioning the strategy as a differentiated alternative to conventional global equity approaches.
Summary
Janus Henderson Investors announced the launch of the Horizon Discovering New Alpha (DNA) Fund on January 8, 2026, a global equity vehicle designed to capture alpha beyond traditional index-driven investing. The fund represents a strategic response to market concentration concerns, where performance increasingly depends on a narrow cohort of mega-cap companies. DNA is structured as a globally diversified portfolio of approximately 50 high-conviction stocks aligned with structural market trends expected to define future growth.
The fund launches under an exclusive distribution agreement with HSBC, making it available initially to HSBC Private Bank and Premier clients across Asia, Europe, US Offshore, and the Middle East for a six-month exclusive period. This partnership reflects both institutions' commitment to delivering differentiated investment solutions to sophisticated wealth management clients in key markets.
The DNA Fund's investment approach distinguishes itself through a proprietary optimization framework that minimizes biases and enhances diversification across sectors, market capitalizations, and geographies. Rather than concentrating in large-cap or technology-heavy exposures—as evidenced by NASDAQ-100's ~60% large-cap concentration and ~70% top-10 holdings weighting—DNA applies thematic idea generation around seven transformation areas: smarter automation, mobility, lifestyle shifts, longevity, biotechnology, sovereignty, and net zero 2.0. This thematic framework guides portfolio managers to identify emerging opportunities aligned with long-term structural growth drivers.
Portfolio leadership rests with Richard Clode and Nick Harper, who integrate insights from Janus Henderson's global team spanning technology, healthcare, financials, real estate, emerging markets, sustainability, and natural resources. The fund combines the firm's experienced stock-pickers' best ideas into a balanced global equity portfolio, reflecting a conviction-driven approach rather than index replication. This structure positions DNA to capture differentiated returns amid evolving global dynamics while addressing investor concerns about excessive concentration in traditional benchmarks and market leaders such as the "Magnificent Seven."
The fund launches under an exclusive distribution agreement with HSBC, making it available initially to HSBC Private Bank and Premier clients across Asia, Europe, US Offshore, and the Middle East for a six-month exclusive period. This partnership reflects both institutions' commitment to delivering differentiated investment solutions to sophisticated wealth management clients in key markets.
The DNA Fund's investment approach distinguishes itself through a proprietary optimization framework that minimizes biases and enhances diversification across sectors, market capitalizations, and geographies. Rather than concentrating in large-cap or technology-heavy exposures—as evidenced by NASDAQ-100's ~60% large-cap concentration and ~70% top-10 holdings weighting—DNA applies thematic idea generation around seven transformation areas: smarter automation, mobility, lifestyle shifts, longevity, biotechnology, sovereignty, and net zero 2.0. This thematic framework guides portfolio managers to identify emerging opportunities aligned with long-term structural growth drivers.
Portfolio leadership rests with Richard Clode and Nick Harper, who integrate insights from Janus Henderson's global team spanning technology, healthcare, financials, real estate, emerging markets, sustainability, and natural resources. The fund combines the firm's experienced stock-pickers' best ideas into a balanced global equity portfolio, reflecting a conviction-driven approach rather than index replication. This structure positions DNA to capture differentiated returns amid evolving global dynamics while addressing investor concerns about excessive concentration in traditional benchmarks and market leaders such as the "Magnificent Seven."
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.